Healthcare Industry News: blood glucose monitor
News Release - June 13, 2006
New Study Assesses Accuracy of Abbott's Investigational FreeStyle Navigator(TM) Continuous Glucose Monitoring SystemClinical Results Presented at ADA Scientific Sessions Suggest Accuracy and Stability Over Five Days of Wear
WASHINGTON, June 13 (HSMN NewsFeed) -- Abbott announced today the presentation of results from a new study designed to assess the accuracy of the FreeStyle Navigator(TM) Continuous Glucose Monitoring System for people with diabetes. The study met its primary endpoint of demonstrated accuracy and stability over five days of wear.
Study results were discussed by William L. Clarke, M.D., professor of pediatrics at the University of Virginia Health System, in a presentation today during the 66th annual Scientific Sessions of the American Diabetes Association.
FreeStyle Navigator Continuous Glucose Monitoring System is an investigational device under FDA review. The system includes a five-day sensor, a transmitter, and a wireless receiver with a built-in FreeStyle® blood glucose monitoring system. The system is designed to provide glucose readings once per minute, high / low glucose alarms and projected glucose alarms.
The accuracy of FreeStyle Navigator was assessed in 58 subjects ranging in age from 18 to 64. Comparison of the FreeStyle Navigator system measurements (n=20,362) with a laboratory reference method (YSI) gave a mean absolute relative difference of 12.8% and a median absolute relative difference of 9.3%. On the Clarke Error Grid (CEG), 81.7% (n=16627) of measurements were in zone A, and 16.7% (n=3398) were in zone B (as compared to YSI). The Clarke Error Grid compares readings from a lab reference to a reading from a glucose monitoring device at a specific point in time. The variance between the two readings is placed on a grid within clinical categories, also known as zones. Each zone is labeled A, B, C, D, or E. Points in the A zone are clinically accurate and most consistent with the lab reference value. B zone readings are clinically acceptable. Points in the C, D, and E zones are progressively less accurate.
"Frequent and accurate glucose monitoring is an essential element of achieving tight glycemic control. The accuracy, particularly in the A zone, of continuous glucose monitoring sensors is critical to assessing the benefits that patients can derive from the technology," said Dr. Clarke. "In clinical studies presented by Abbott earlier this week, the FreeStyle Navigator system, under development, has set a new threshold for point glucose accuracy in a continuous glucose monitoring system."
"We look forward to making FreeStyle Navigator available to people with diabetes and we're very pleased that the system continues to demonstrate excellent accuracy in clinical studies," said Ed Fiorentino, president, Abbott Diabetes Care.
About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, Calif., is a worldwide leader in developing, manufacturing and marketing glucose monitoring systems designed to help patients better manage their diabetes. Abbott Diabetes Care is committed to developing products to reduce the discomfort and inconvenience of blood glucose monitoring and introducing systems that are easier to use, require smaller blood samples and provide faster results.
Abbott Diabetes Care has several leading-edge glucose monitoring systems and test strips in the United States for use in both home and hospital settings; leading brands include FreeStyle®, FreeStyle Flash® and Precision Xtra(TM). Additional information about Abbott Diabetes Care may be found at http://www.abbottdiabetescare.com .
Abbott (NYSE: ABT ) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott's FreeStyle Libre(R) 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer(TM) Steerable Delivery Sheath for the Company's Amulet(TM) Device